News archives

Preliminary results for the year ended 31 August 2001

5 December 2001

For the 2001 Preliminary Results

Commences repeat dose clinical study of dementia treatment, P58

8 November 2001

Phytopharm plc (PYM: London Stock Exchange) (”Phytopharm”) announces today the start of a clinical study to evaluate the safety, tolerability, pharmacokinetic profile and effect on cognitive performance of its oral product, P58. This product is under development as a treatment for age-related cognitive dysfunction, which typically presents as memory loss, dementia and Alzheimer’s disease.

Results of P54 trial in canine osteoarthritis

31 July 2001

Phytopharm plc (PYM: London Stock Exchange) (”Phytopharm”) announces today the results of a randomised, double blind, placebo-controlled study of its natural anti-inflammatory product P54 for the treatment of canine osteoarthritis (OA). P54 is a patented non-steroidal anti-inflammatory drug (NSAID) manufactured from 2 related plant species.

Proof of Principle Clinical Study of P57 for Obesity

5 July 2001

Phytopharm plc (PYM: London Stock Exchange) (”Phytopharm”) announces today the successful completion of the second stage of its clinical study of P57 for obesity. The objectives of this stage of the study include evaluation of the safety, tolerability and pharmacokinetic profile of P57, a patented oral product licensed to Pfizer Inc., which is under development as an appetite suppressant for the treatment of obesity.

Appointment of Chief Operating Officer

11 June 2001

Phytopharm plc (PYM: London Stock Exchange) (”Phytopharm”) announces the appointment today of Dr Daryl Rees as Chief Operating Officer for the Company. In this executive role he will have responsibility for the conduct of Phytopharm’s research and development programmes as well as direct responsibility for the Company’s manufacturing operations worldwide.

Interim results for the period to 28 February 2001

30 April 2001

For the 2001 Interim Results

Proof of Principle Phase I Clinical Study of P57 for Obesity

10 April 2001

Phytopharm plc (PYM: London Stock Exchange) (”Phytopharm”) announces today the successful completion of the first stage of its clinical study of P57 for obesity. The objectives of the study include evaluation of the safety, tolerability, pharmacokinetic profile and effect on calorie intake of Phytopharm’s patented oral product P57. This P57 product licensed to Pfizer Inc., is under development as an appetite suppressant for the treatment of obesity.

Commences Proof of Principle Clinical Study of P57 for Obesity

7 March 2001

Phytopharm plc (PYM: London Stock Exchange) (”Phytopharm”) announces today the start of a proof of principle clinical study to evaluate the safety, tolerability, pharmacokinetic profile and effect on calorie intake of its patented oral product P57. This product (licensed to Pfizer Inc.) is under development as an appetite suppressant for the treatment of obesity.

Preliminary Results for the Year Ended 31 August 2000

29 November 2000

For the 2000 Preliminary Results

Results of Phase I clinical trials in Alzheimer’s disease and related dementias

29 November 2000

Phytopharm plc (PYM: London Stock Exchange) (”Phytopharm”) announces today the results of a Phase I single dose escalation study of P58, its novel, patented product for the treatment of Alzheimer’s disease.